Antiplatelet effects of citalopram in patients with ischaemic stroke:A randomized, placebo-controlled, double-blind study by Kraglund, Kristian Lundsgaard et al.
 
  
 
Aalborg Universitet
Antiplatelet effects of citalopram in patients with ischaemic stroke
A randomized, placebo-controlled, double-blind study
Kraglund, Kristian Lundsgaard; Mortensen, Janne Kaergaard; Johnsen, Søren Paaske;
Andersen, Grethe; Grove, Erik Lerkevang
Published in:
Scientific Reports
DOI (link to publication from Publisher):
10.1038/s41598-019-56487-8
Creative Commons License
CC BY 4.0
Publication date:
2019
Document Version
Publisher's PDF, also known as Version of record
Link to publication from Aalborg University
Citation for published version (APA):
Kraglund, K. L., Mortensen, J. K., Johnsen, S. P., Andersen, G., & Grove, E. L. (2019). Antiplatelet effects of
citalopram in patients with ischaemic stroke: A randomized, placebo-controlled, double-blind study. Scientific
Reports, 9(1), [20048]. https://doi.org/10.1038/s41598-019-56487-8
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners
and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.
            ? Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
            ? You may not further distribute the material or use it for any profit-making activity or commercial gain
            ? You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us at vbn@aub.aau.dk providing details, and we will remove access to
the work immediately and investigate your claim.
Downloaded from vbn.aau.dk on: November 25, 2020
1Scientific RepoRtS |         (2019) 9:20048  | https://doi.org/10.1038/s41598-019-56487-8
www.nature.com/scientificreports
Antiplatelet effects of citalopram 
in patients with ischaemic stroke: 
A randomized, placebo-controlled, 
double-blind study
Kristian Lundsgaard Kraglund1,2, Janne Kaergaard Mortensen1, Søren Paaske Johnsen3,5, 
Grethe Andersen1,5 & Erik Lerkevang Grove  4,5*
We evaluated the effect of SSRI treatment on platelet aggregation in patients with ischaemic stroke 
and included patients from the randomized double-blind controlled study of citalopram in acute 
ischaemic stroke (TALOS). Patients on clopidogrel were included 6 months after acute ischaemic stroke. 
Platelet parameters, including P2Y12 platelet reactivity using the VerifyNow System, were measured 
at the last day of study treatment and repeated after a 14-day wash-out period. A total of 60 patients 
were included (n = 32 randomized to citalopram). Platelet aggregation levels did not differ between 
the citalopram group (mean 116, 95% CI 89 to 143) and the placebo group (mean 136, 95% CI 109 to 
163) (On-treatment, p = 0.14). Similarly, there was no significant change in platelet aggregation in 
the citalopram group from on-treatment to post-treatment (mean difference 2.0; 95% CI −18 to 14). 
Platelet count, size and turnover were not affected by SSRI treatment. In conclusion, SSRI therapy did 
not lead to statistically significant inhibition of platelet aggregation in ischaemic stroke patients treated 
with clopidogrel.
Selective serotonin reuptake inhibitors (SSRIs) are widely used after stroke1,2. Observational studies have indi-
cated an increased bleeding risk and a protective effect of SSRIs against recurrent cardiovascular events in patients 
with ischaemic stroke.
Platelets lack the enzyme needed to produce serotonin (5-HT), but a 5-HT transporter (5-HTT) enables rapid 
uptake from plasma3. If a thrombotic event occurs, 5-HT is released3. 5-HT is a relatively weak platelet activator 
per se, but facilitates platelet response to other agonists, including adenosine diphosphate (ADP)4. SSRIs inhibit 
the 5-HTT and reduce platelet 5-HT concentrations by almost 90%. This inhibits platelet-mediated haemostasis 
and may reduce the risk of cardiovascular events5,6.
This is a predefined substudy (Ethical committee approval no 1-10-72-183-13, see also supplementum in7) 
of the TALOS trial testing the SSRI citalopram in non-depressed patients with acute ischaemic stroke7,8. TALOS 
showed similar risks of cardiovascular events between treatment groups and a borderline statistical significant 
effect on functional recovery in the on-treatment analysis. Clopidogrel is frequently used as secondary preven-
tion in patients with ischaemic stroke9,10. We compared platelet aggregation levels in patients with ischaemic 
stroke treated with clopidogrel in addition to citalopram vs placebo. We hypothesized that patients treated with 
citalopram would have lower platelet aggregation levels compared to placebo-treated patients. Also, that plate-
let aggregation would increase in patients randomized to citalopram when measurements were repeated after a 
wash-out period.
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Materials and Methods
Study design and subjects. Patients were included from the TALOS trial: an investigator-initiated rand-
omized, controlled, double-blind trial7,8. In brief, patients with first-ever ischaemic stroke within the previous 7 
days were enrolled from three Danish stroke units. All patients were treated in accordance with stroke guidelines 
and were randomized to either citalopram or placebo. A total of 60 consecutive patients treated with clopidogrel 
were included 6 months after acute ischaemic stroke as described below.
The study was investigator-driven and conducted according to the principles of the Declaration of Helsinki 
and monitored according to Good Clinical Practice guidelines. Written informed consent was obtained from 
all participants. The protocol was approved by the Committees on Health Research Ethics (1-10-72-183-13), 
EudraCT number is 2013-002253-30 and clinical trial registration number (clinicaltrials.gov) for the main 
TALOS study is NCT01937182.
Study medications. Patients were randomly assigned 1:1 to receive either citalopram (Sandoz, Copenhagen, 
Denmark) administered orally once daily for 6 months at a dose of 20 mg (10 mg if aged ≥65 years and/or reduced 
liver/kidney function) or placebo. In order to standardize the time between drug ingestion and platelet function 
testing, intake of the study drug and clopidogrel (75 mg once daily) was scheduled to occur at 8 a.m. on the day 
before and at the day of testing.
Blood sampling. Patients were scheduled for follow-up between noon and 3 p.m. on the last day of treatment 
with study drug (On-treatment) and 14 days later (Post-treatment). Using minimal stasis, blood samples were 
taken from a forearm vein using a 21-gauge needle:
 1. 6 mL tube (discharged to avoid stasis-induced platelet activation).
 2. Vacuette 9NC Coagulation Sodium Citrate 3.2% 2 mL tube (VerifyNow testing).
 3. Vacutainer 6 mL (centrifuged for 15 min at 1000 × g at 5 °C and stored at −80 °C for later analysis).
 4. Vacutainer tube K2EDTA 10 mL (other analyses including platelet count and reticulated platelets).
Platelet aggregation measurements. Platelet aggregation was measured using the VerifyNow P2Y12 
platelet reactivity system (Accriva Diagnostics, San Diego, CA, USA). VerifyNow is a turbidimetric-based optical 
detection system measuring platelet aggregation in whole blood11. The VerifyNow has high reproducibility12. 
Results are reported as P2Y12 Reaction Units (PRU).
Other platelet parameters. Using a Sysmex XN-8000 (Sysmex, Kobe, Japan), we measured total platelet 
count, immature platelet count, platelet-large cell ratio, mean platelet volume, white and red blood cell count, 
haemoglobin, and reticulocytes.
Statistical analyses. Samples from the two groups (citalopram vs placebo) were compared using student’s 
t-test. P-values below 5% were considered statistically significant. No previous studies in similar populations 
were available before study initiation and, therefore, no formal sample size calculation was performed. Based on 
previous platelet function studies using the VerifyNow, a total of 25–30 patients in each group was considered 
appropriate, and consecutive patients were asked to participate, until 60 patients had been included. Statistical 
analyses were performed using Stata 13.1 (StataCorp, College Station, TX, USA).
Results
The two groups were well balanced with respect to age ((mean (SD), 71 (9.3) years), 38% females). The median 
time from intake of study medication to blood sampling did not differ between groups: 5.1 h in the citalopram 
group and 4.8 h in the placebo group.
ADP-induced platelet aggregation (PRU) levels did not differ between the citalopram group (mean 116, 95% 
CI 89 to 143) and the placebo group (mean 136, 95% CI 109 to 163, p = 0.14) when comparing patients during 
treatment (Table 1). On-treatment PRU values in the citalopram group (mean 116, 95% CI 89 to 143) did not 
differ from the values measured Post-treatment (mean 114; 95% CI 88 to 139). Other platelet parameters are pre-
sented in Table 1. Platelet turnover, quantified using immature, reticulated platelets13, showed no significant dif-
ference between groups or between measurements in the citalopram group. Haemoglobin levels were significantly 
lower in patients allocated to citalopram treatment. This was observed both for the On-treatment (p = 0.041) and 
the Post-treatment measurement (p = 0.001).
Discussion
In this predefined substudy of the randomized controlled trial TALOS, we evaluated potential antiplatelet effects 
of the SSRI citalopram in ischaemic stroke patients treated with the P2Y12 inhibitor clopidogrel for prevention 
of recurrent stroke. The primary outcome, PRU, was measured during treatment with clopidogrel and citalo-
pram/placebo and again after wash-out. Platelet function testing was performed after a standardised time interval 
between drug ingestion and blood sampling, which was performed at the same time of the day to minimise any 
diurnal variation in platelet aggregation. Platelet function testing did not show any significant difference in PRU 
between groups at both measurements (i.e. during combined therapy and on clopidogrel monotherapy after a 
wash-out period). Similarly, no difference was observed between patients allocated to citalopram, when measure-
ments were taken on on-treatment and repeated post-treatment.
Previous studies have indicated an increased risk of bleeding, when SSRIs are given in combination with aspirin 
and/or clopidogrel14, but these observational studies are to some extent hampered by confounding-by-indication. 
This is the first randomized study investigating platelet aggregation levels in patients receiving citalopram/placebo 
3Scientific RepoRtS |         (2019) 9:20048  | https://doi.org/10.1038/s41598-019-56487-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
during concomitant treatment with clopidogrel, and the study thus provides novel information with respect to 
the cardiovascular benefits and risks with SSRI. The design of the TALOS study allowed repetitive measurements 
in the same patients receiving either citalopram or placebo in combination with clopidogrel, providing a unique 
opportunity to analyse citalopram’s platelet inhibitory effect.
In vitro studies have reported 5-HT as a weak platelet agonist per se15, and 5-HT primes platelet activation 
and potentiates procoagulant responses of platelets, including that from ADP16. In addition, studies have shown 
decreased platelet aggregation in 5-HTT knockout mice17.
The standardisation of blood sampling kept the variability from other parameters to a minimum. Importantly, 
all study subjects were treated with clopidogrel, which may have reduced the ability to detect minor platelet inhi-
bition by SSRIs. However, studying stroke patients without any antithrombotic treatment would entail ethical 
challenges. Moreover, platelet function testing was performed 6 months after ischaemic stroke, and one might 
hypothesize that platelet reactivity, and thus the potential for detecting inter-group differences when adding cit-
alopram, would have been larger in the early phase after ischaemic stroke. In this population of stroke patients 
treated with clopidogrel mono antithrombotic therapy, we evaluated platelet function based on the ADP pathway, 
and it cannot be excluded that SSRIs may also inhibit platelet aggregation by non-ADP pathways. Accordingly, 
recent data indicate that citalopram reduce collagen-induced platelet aggregation by concentration-dependent 
inhibition of convulxin-related aggregation, serotonin release and activation of αIIbβ318. Another recent study19 
reported evidence for two novel mechanisms of citalopram-induced platelet inhibition, including inhibition of 
so-called CalDAG-GEFI/Rap1 signalling and competitive antagonism of glycoprotein VI in platelets. Finally, 
platelet aggregation levels were numerically lower during treatment with citalopram in our study, and results 
might have differed in a larger study population. The results of this platelet function study do not indicate that 
treatment with citalopram is beneficial or harmful in stroke patients treated with clopidogrel, but more studies 
are warranted to evaluate the effect of SSRIs on non-ADP dependent platelet function and to evaluate clinical 
implications of combined treatment with SSRIs and antithrombotic therapy.
In conclusion, although SSRI treatment may reduce the risk of recurrent cardiovascular events according to 
prior studies, our data do not support the hypothesis that citalopram provides substantial platelet inhibition in 
patients with ischaemic stroke treated with clopidogrel.
Compliance with ethical standards. The Danish Council for Independent Research, Danish Regions 
Medical Research Council, and Central Denmark Region Research Council provided funding for this study, but 
had no role in the study design; in the collection, analysis and interpretation of data; in the writing of the article; 
or in the decision to submit the paper for publication.
Written informed consent was obtained from all participants. The study was conducted in accordance with 
the ethical standards of the national research committee and with the 1964 Helsinki declaration and its later 
amendments. Approvals were obtained from regulatory agencies and the Committees on Health Research Ethics 
as described above in the section on Methods.
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